Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project

Holly J. Meany, Wendy B. London, Peter F. Ambros, Katherine K. Matthay, Tom Monclair, Thorsten Simon, Alberto Garaventa, Frank Berthold, Akira Nakagawara, Susan L. Cohn, Andrew D J Pearson, Julie R. Park

Research output: Contribution to journalArticle

Abstract

Background: International Neuroblastoma Staging System (INSS) Stage 3 neuroblastoma is a heterogeneous disease. Data from the International Neuroblastoma Risk Group (INRG) database were analyzed to define patient and tumor characteristics predictive of outcome. Procedure: Of 8,800 patients in the INRG database, 1,483 with INSS Stage 3 neuroblastoma and complete follow-up data were analyzed. Secondary analysis was performed in 1,013 patients (68%) with MYCN-non-amplified (NA) tumors. Significant prognostic factors were identified via log-rank test comparisons of survival curves. Multivariable Cox proportional hazards regression model was used to identify factors independently predictive of event-free survival (EFS). Results: Age at diagnosis (P

Original languageEnglish
Pages (from-to)1932-1939
Number of pages8
JournalPediatric Blood and Cancer
Volume61
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

    Fingerprint

Keywords

  • Biologic factor
  • Neuroblastoma
  • Treatment outcome

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Meany, H. J., London, W. B., Ambros, P. F., Matthay, K. K., Monclair, T., Simon, T., Garaventa, A., Berthold, F., Nakagawara, A., Cohn, S. L., Pearson, A. D. J., & Park, J. R. (2014). Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 61(11), 1932-1939. https://doi.org/10.1002/pbc.25134